Management Strategies for Mixed GH and Prolactin-Secreting Macroadenomas Following Surgical Failure: A Case Report

Introduction: Acromegaly is a rare endocrine disorder characterized by excessive growth hormone (GH) production, leading to various complications. The primary treatment goal is to reduce GH and IGF-I levels, with options including surgical resection, medical therapy (e.g., somatostatin receptor ligands (SRLs), dopamine agonists, and pegvisomant), and radiotherapy. The rate of biochemical control reported varies widely across different studies. Case Presentation: A 28-year-old woman with clinically evident acromegaly, characterized by physical changes, was referred due to symptoms including snoring, dental spacing, profuse sweating, joint aches, headaches, visual blurring, and amenorrhea. She had no hypertension, galactorrhea, or diabetes mellitus. Clinical examination revealed a clear acromegalic phenotype and a thyroid goiter. Initial tests showed elevated IGF-1(687 µg/L), high prolactin (165 ng/ml), normal glucose tolerance, and normal lipid profile. MRI identified a large hyperintense mass with supra- and latero-sellar extension. Campimetry revealed a bitemporal hemianopsia in both the right and left eyes. The patient underwent transsphenoidal surgery, with histology confirming a GH/PRL adenoma. At 3 months, residual tumor was still present, and IGF-1 levels were elevated. The treatment with cabergoline and lanreotide for four years did not achieve biological or tumor control of the tumor residue, despite dosage increases. However, switching to pasireotide led to the normalization of IGF-1 levels after four months, although this was accompanied by an increase in fasting blood glucose levels. Conclusion: In summary, this case highlights the effective use of pasireotide, in combination with the dopamine agonist cabergoline, for managing acromegaly in a patient with residual disease. It underscores the importance of personalized treatment plans and the necessity for ongoing monitoring and therapy adjustments to achieve the best possible outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Innovations in Medical Research
Published
2024-12-01
DOI
https://doi.org/10.56397/jimr/2024.12.02
Primary Topic
Hyperglycemia and glycemic control in critically ill and hospitalized patients
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management Strategies for Mixed GH and Prolactin-Secreting Macroadenomas Following Surgical Failure: A Case Report

M. Thabet, Hamza El Fekih, Y. Hasni, Amel Maaroufi et al.
Journal of Innovations in Medical Research
Hyperglycemia and glycemic control in critically ill and hospitalized patients
article

Management Strategies for Mixed GH and Prolactin-Secreting Macroadenomas Following Surgical Failure: A Case Report

M. Thabet, Hamza El Fekih, Y. Hasni, Amel Maaroufi, Imen Halloul, N. Thabet, Ghada SAAD, Sawsen Nouira, Wiem SSAFI
article en

Abstract

Introduction: Acromegaly is a rare endocrine disorder characterized by excessive growth hormone (GH) production, leading to various complications. The primary treatment goal is to reduce GH and IGF-I levels, with options including surgical resection, medical therapy (e.g., somatostatin receptor ligands (SRLs), dopamine agonists, and pegvisomant), and radiotherapy. The rate of biochemical control reported varies widely across different studies. Case Presentation: A 28-year-old woman with clinically evident acromegaly, characterized by physical changes, was referred due to symptoms including snoring, dental spacing, profuse sweating, joint aches, headaches, visual blurring, and amenorrhea. She had no hypertension, galactorrhea, or diabetes mellitus. Clinical examination revealed a clear acromegalic phenotype and a thyroid goiter. Initial tests showed elevated IGF-1(687 µg/L), high prolactin (165 ng/ml), normal glucose tolerance, and normal lipid profile. MRI identified a large hyperintense mass with supra- and latero-sellar extension. Campimetry revealed a bitemporal hemianopsia in both the right and left eyes. The patient underwent transsphenoidal surgery, with histology confirming a GH/PRL adenoma. At 3 months, residual tumor was still present, and IGF-1 levels were elevated. The treatment with cabergoline and lanreotide for four years did not achieve biological or tumor control of the tumor residue, despite dosage increases. However, switching to pasireotide led to the normalization of IGF-1 levels after four months, although this was accompanied by an increase in fasting blood glucose levels. Conclusion: In summary, this case highlights the effective use of pasireotide, in combination with the dopamine agonist cabergoline, for managing acromegaly in a patient with residual disease. It underscores the importance of personalized treatment plans and the necessity for ongoing monitoring and therapy adjustments to achieve the best possible outcomes.

Journal of Innovations in Medical ResearchVol. 3(4)
Hôpital Farhat Hached (TN), University of Sousse (TN)
Good health and well-being
Openalex Percentile: Top 62%
Hyperglycemia and glycemic control in critically ill and hospitalized patients
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.